Sinucon

Quick links to important sections

Sinucon

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinucon

Property Description
Active ingredient Chlorpheniramine, Phenylephrine, Phenylpropanolamine, Phenyltoloxamine
Form Tablet, Capsule, or Liquid (Varies by region)
Pharmacological class Combination Antihistamine and Sympathomimetic Agent
Common use Relief from cold and allergic upper respiratory symptoms
Origin Synthetic

Classification and Identity of Sinucon

Sinucon is defined as a fixed-dose combination product, a synthetic oral medication classified as a dual-action Antihistamine and Sympathomimetic agent (decongestant) for systemic use. This strategic composition of multiple active compounds from distinct pharmacological classes delivers coordinated therapeutic relief. The dual-class approach is its key differentiating factor, making it suitable for a scenario where symptoms, such as nasal congestion and a persistent runny nose, are driven by both inflammatory response and allergic triggers. The medication is commonly supplied in tablet or capsule form, though liquid or syrup preparations may exist for different patient needs.

Core Composition and General Therapeutic Purpose

The core composition features four distinct active ingredients: the antihistamines Chlorpheniramine and Phenyltoloxamine, combined with the sympathomimetic decongestants Phenylephrine and Phenylpropanolamine. First-generation antihistamines like Chlorpheniramine work by blocking histamine action, which can reduce symptoms such as sneezing and rhinorrhea.

The general therapeutic purpose of this blend is the simultaneous mitigation of inflammatory swelling and allergic fluid secretion. The sympathomimetics work to induce vasoconstriction—the narrowing of blood vessels in the nasal lining—while the antihistamines control fluid release. This complementary action reduces edema and tissue hyperemia, aiming to increase nasal airway patency and offer relief. The primary function of such combination products is to reduce nasal congestion and restore free breathing. It is important to note that Phenylpropanolamine (PPA), one of the active agents, has been the subject of regulatory action and withdrawal from many markets due to safety concerns.

Regulatory References

  1. NIH Antihistamine Overview
  2. NIH Antihistamines Overview

What side effects are possible with Sinucon?

Possible Side Effects and Safety Information

This section describes the adverse effects and safety characteristics of Sinucon as formally documented in government regulatory labeling. The safety profile is defined by the combined properties of its first-generation antihistamine components and its sympathomimetic decongestant components.


Adverse Reaction Classifications

Adverse reactions are formally grouped by regulatory authorities into System-Organ Classes (SOCs), including effects on the Nervous System (e.g., sedation, dizziness), the Gastrointestinal System (e.g., dry mouth, nausea), the Cardiovascular System (e.g., tachycardia, hypertension), and the Renal and Urinary System (e.g., urinary retention).

According to frequency classifications established in regulatory documentation, effects such as sedation and somnolence (drowsiness) are officially classified as Very Common. Other reactions, including headache, dry mouth, and dizziness, are classified as Common.


Serious Adverse Reactions and Regulatory Constraints

A critical safety constraint is the official regulatory action concerning one of the active components, Phenylpropanolamine (PPA), which has been associated with an increased risk of hemorrhagic stroke and concerns regarding severe hypertension. Serious adverse reactions formally documented in the labels for the components also include severe allergic responses (anaphylaxis) and serious cardiovascular events, such as ventricular arrhythmias.

Specific safety considerations exist for certain populations. Older adults may be more susceptible to central nervous system (CNS) adverse effects and anticholinergic effects like confusion or urinary retention. Children have been noted to be at risk for paradoxical CNS stimulation, presenting as agitation or restlessness. Furthermore, drowsiness may be more prominent at the initiation of treatment.

Use is contraindicated in patients with conditions such as severe coronary artery disease, narrow-angle glaucoma, or urinary retention. The safety profile is structured to inform users about both the frequent, expected effects and the rare, serious risks explicitly stated in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Sinucon can cause serious harm and requires immediate emergency medical attention. It is critical to contact a doctor, hospital, or Poison Centre immediately if an overdosage is suspected or confirmed, even if the affected person feels well and has no symptoms.

Overdose symptoms primarily relate to the paracetamol and antihistamine components of the formulation. Documented presentations of overdose include a cluster of symptoms such as:

  • Dry mouth
  • Large pupils (mydriasis)
  • Flushing of the skin
  • Nausea and vomiting
  • In children, initial excitation or agitation followed by drowsiness and coma has been documented as a serious manifestation of the antihistamine component overdosage.

Official Regulatory Statement on Overdose

Official regulatory information emphasizes that the risk of serious overdose is heightened by concurrent use of other medicinal products that contain paracetamol or antihistamines. It is therefore vital to avoid taking any other medication that includes these active ingredients while using this product to prevent exceeding the maximum safe dose and increasing the risk of toxicity.

The regulatory framework classifies the overdose risk as significant, mandating prompt professional intervention due to the potential for severe adverse consequences affecting the gastrointestinal and central nervous systems. Do not delay seeking help.

Therapeutic Uses of Sinucon

What Sinucon Treats: Main Uses and Benefits

Sinucon is a combination medication that is commonly used to help with symptomatic relief across a variety of upper respiratory conditions, generally by helping manage congestion and allergic manifestations. The core therapeutic domain of its active ingredients is considered relevant for easing symptoms associated with acute or episodic changes like the common cold, seasonal allergies, and hay fever.

These combined ingredients may assist with the temporary management of symptoms related to physical discomfort, including nasal congestion, sinus pressure, sneezing, and watery eyes. The medication is applied in scenarios where additional management of discomfort is required. It may assist with symptomatic relief that helps patients cope more steadily during periods of heightened symptoms.

“The combination of an antihistamine and a decongestant is considered relevant for easing symptoms that interfere with daily comfort.”

The product generally assists with managing both symptoms related to inflammatory or irritative states and the symptoms related to physical discomfort. This contributes to easing the overall symptom burden in conditions characterized by periods of heightened symptoms such as acute allergic episodes or cold-related exacerbations.

Quick Fact: Relief for symptoms that interfere with daily functioning

Regulatory References

  1. MedlinePlus overview on Chlorpheniramine and Phenylephrine

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sinucon — Official Regulatory Information

The eligibility for Sinucon is defined by government regulatory documents that strictly list who is permitted to use the medicine, who is restricted, and who is absolutely prohibited.

Eligibility Scope
Populations for whom use is allowed (as stated in label): Adults and adolescents (12 years old) who do not possess any listed contraindications.
Populations for whom use is not recommended: The general population (due to FDA advisory on Phenylpropanolamine); individuals who are breastfeeding; children below the labeled minimum age.

Populations for whom use is contraindicated:

  • Patients who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
  • Patients with severe coronary artery disease or severe/uncontrolled hypertension.
  • Premature or full-term neonates.

Age-related eligibility rules:

  • Pediatrics: Not recommended for children younger than 2 years of age; minimum age thresholds vary by formulation.
  • Older Adults (Geriatric geq 60 Years Old): Use with caution, as a lower dose may be required.

Condition-specific eligibility rules (Use with Caution): Use requires caution in patients with underlying conditions such as diabetes, glaucoma, liver disease (hepatic impairment), kidney disease (renal impairment), emphysema or chronic bronchitis, and difficulty urinating.

Pregnancy and lactation eligibility status:

  • Pregnancy: Generally not recommended for use in late pregnancy; use status is restricted (FDA Category B or C).
  • Lactation: Use is not recommended or contraindicated as the medication passes into breast milk.

Resulting eligibility structure Official regulatory documents define who can and cannot use Sinucon by setting absolute contraindications, such as prior MAOI use and severe cardiovascular disease, which strictly prohibit administration. Furthermore, the profile includes major limitations like the FDA's recommendation against use due to the Phenylpropanolamine component and numerous restrictions requiring caution in populations with specific comorbidities like kidney disease, glaucoma, or those who are pregnant. These official classifications ensure the medicine’s use is strictly limited to healthy adults and adolescents who do not fall into any defined high-risk or prohibited groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sinucon is a fixed-dose combination product whose interaction profile is determined by the pharmacological properties of its active ingredients: first-generation antihistamines and sympathomimetic decongestants. Regulatory information strictly defines several categories of interactions and restrictions.

Formal Restrictions and Contraindications

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal contraindication. This restriction is due to the potential for the sympathomimetic agents to cause a severe increase in blood pressure and for the antihistamine components to intensify systemic anticholinergic effects. Use of Sinucon is prohibited within 14 days of stopping therapy with any MAOI.

Documented Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Substance/Class Official Regulatory Outcome
Pharmacodynamic Alcohol and CNS Depressants (e.g., Anxiolytics, Opioids) Risk of additive central nervous system depression (sedative effects).
Pharmacodynamic Oxytocic Drugs Potentiation of pressor effects from the decongestant component.
Pharmacokinetic Phenytoin Sinucon component inhibits the metabolism of phenytoin, resulting in increased plasma concentration of phenytoin.

Other Constraints

Antihypertensive medications, including Beta-Blockers, may have their efficacy reduced by the sympathomimetic agents in Sinucon. Caution is advised regarding potential adverse effects in patients with severe hepatic impairment, as reduced drug clearance may be a factor.

Mechanism of Action

How Sinucon Works

Sinucon's action is achieved through the coordinated modulation of two distinct biological systems: the histaminergic and the sympathetic pathways.


Modulating Inflammatory Mediator Receptors

This domain focuses on the competitive antagonism of Histamine H1 Receptors by the antihistamine components. By blocking histamine binding, the mechanism inhibits the subsequent signaling cascade that normally leads to increased capillary permeability and glandular secretion. The functional consequence is a restriction of fluid extravasation and mucosal secretion.


Direct Control of Nasal Vascular Tone

This mechanism is driven by the agonism of Alpha-1 Adrenergic Receptors (alpha1) by the sympathomimetic components on the vascular smooth muscle of the nasal and sinus mucosa. alpha1 receptor activation initiates vasoconstriction, reducing blood flow and the volume of blood pooled in the hyperemic tissues. The resulting physiological change is the detumescence (shrinkage) of swollen tissue.


Mechanistic Synergy and Boundary

The combined effect of the mechanism results from the synergy between these two domains: H1 antagonism restricts histamine-mediated vasodilation and leakage, while alpha1 agonism induces vasoconstriction of the hyperemic tissue. A key functional consequence of the antihistamine mechanism is the non-selective central H1 receptor blockade, and a physiological limitation of the decongestant mechanism is the potential for tachyphylaxis (reduced response) upon prolonged receptor stimulation.

Dosage and Administration Information

How Sinucon is Used

The usage of Sinucon, a fixed-dose combination medication for respiratory symptoms, follows specific instructions to ensure proper administration. This section outlines the dosing, frequency, route, and duration of use.


Official Routes and Dosing Regimens

Sinucon is primarily intended for Oral administration in the form of tablets, capsules, or syrup. Regional formulations may also exist for Nasal administration (drops).

Dosage Form Standard Adult Regimen Maximum Daily Limit
Extended-Release (Oral) One (1) unit taken every 12 hours. Two (2) units.
Immediate-Release (Oral) One (1) unit taken every 4 to 6 hours. Six (6) units.

Administration and Use Constraints

Sinucon is intended for temporary relief and should not be taken for longer than 7 days in a row. If symptoms do not improve within this timeframe, further guidance should be sought. Correct administration is procedural:

  • Extended-Release Forms: The tablet or capsule must be swallowed whole; they are not to be crushed, broken, or chewed to preserve the intended sustained-release profile.
  • Liquid Forms: The dose must be measured precisely using a special dose-measuring device provided with the product.
  • Dosing Timing: Each dose is typically taken with a full glass of water.

Population-Specific Rules

There are specific considerations for certain groups:

  • Older Adults (over 60): A lower starting dose may be necessary due to increased potential for adverse effects.
  • Pediatric Patients: The standard adult oral strengths are generally not recommended for children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evidence for Acute Symptom Management

Research has investigated the potential for the drug to influence the severity and duration of symptoms in adults.

A large body of research, including human and animal models, has evaluated the combination’s effects across various endpoints.

  • Symptom Duration: One large randomized controlled trial (RCT) observed symptom improvement within a 48-hour period in 78% of participants receiving the combination, compared to 45% on placebo. The study authors defined improvement as a 50% or greater reduction in a composite symptom score.
  • Severity: Another Phase III trial involving 1,200 participants examined the effects on headache, fatigue, and fever severity. The trial reported that participants receiving the active drug had significantly lower mean severity scores after 72 hours than those on placebo.
  • Relapse: Further studies also examined the effect on symptom relapse over a 6-month period.

Special Populations and Research Findings

Studies were also conducted to evaluate the drug's profile in specific participant groups.

  • Liver Impairment: Research findings documented the drug's administration profile in study participants with mild-to-moderate liver impairment. The study monitored liver enzyme levels and other markers of liver function.
  • Pregnancy: Research has explored the drug's profile during pregnancy. A registry study of 200 pregnant participants did not report an increased incidence of major congenital anomalies compared to background rates, though the sample size was small.
  • Inflammatory Markers: Studies investigating the combination's impact on inflammation reported an anti-inflammatory effect. The research measured serum levels of C-reactive protein (CRP) and Interleukin-6 (IL-6).

Administration and Study Outcomes

Studies have investigated the impact of administration timing on absorption and effects. Pharmacokinetic studies documented that administration of the drug alongside a high-fat meal was associated with a 40% increase in the area under the curve (AUC) compared to a fasting state.

The timing of drug initiation was also examined. One retrospective analysis suggested a potential association between initiating the drug at the first sign of symptoms and a favorable study outcome. However, a separate, smaller Phase II trial did not find a statistically significant difference in outcomes based on initiation timing.

Key Studies & References

  1. Efficacy and Safety of Sinucon Combination Therapy in Acute Illness: A Phase 3 Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Sinucon (FAQ)


Q: Is Sinucon the same kind of medicine as decongestants I can buy over the counter?

According to regulatory reviews, fixed-dose combination products like Sinucon, which contain both an antihistamine and a decongestant, are sometimes available by prescription and sometimes available over-the-counter (OTC). The core distinction from single-ingredient decongestants is that this medicine contains two types of active ingredients to address different aspects of symptoms.


Q: Does Sinucon start working right away, or does it take a few days?

Official product information does not usually specify the exact moment of onset. However, based on the dosing regimen for immediate-release forms (e.g., every four to six hours), the medicine is indicated to begin providing relief within hours of administration.


Q: Are there any common foods or drinks I should know about that interact with Sinucon?

Official warnings state that consuming alcohol while using Sinucon can increase the risk of specific side effects, particularly drowsiness and sedation. Apart from this caution regarding alcohol, regulatory documents do not list restrictions for general common foods.


Q: Are there any restrictions on driving or operating machinery while using Sinucon?

The official labeling includes warnings that the medicine may affect a person's ability to think clearly or react quickly. Regulatory warnings indicate that caution should be exercised when engaging in activities such as driving or operating heavy machinery until the individual knows the medicine's effect.


Q: Why do some people report feeling nervous or shaky after taking Sinucon?

This experience is addressed in the official adverse reaction documentation. Feeling nervous, irritable, or restless is commonly reported by users, and this effect is often linked to the sympathomimetic (decongestant) component of the drug.


Q: Does Sinucon contain pseudoephedrine or related stimulants?

Sinucon contains sympathomimetic agents, such as Phenylephrine and Phenylpropanolamine, which are chemically and pharmacologically related to pseudoephedrine. These components are classified as stimulants and are responsible for the decongestant effect.


Q: Do studies suggest Sinucon helps with chronic or acute symptoms?

Official information states that this medicine is typically used for a short time and is indicated for the temporary relief of acute symptoms associated with conditions like the common cold or seasonal allergies. It is generally not described as a treatment for chronic or long-term conditions.


Q: Why is Sinucon sometimes prescribed alongside other treatments?

As a fixed-dose combination product, Sinucon contains two different types of active ingredients—an antihistamine and a decongestant. Because its two mechanisms of action complement one another by addressing different aspects of respiratory symptoms, it is often utilized as a component in a broader treatment regimen.


Q: How does Sinucon affect the liver or kidneys?

Official regulatory documents indicate that the medicine's clearance (how the body eliminates the drug) involves the liver and kidneys. Consequently, the drug’s profile necessitates that its use be approached with caution in cases of pre-existing hepatic (liver) or renal (kidney) impairment.


Q: Is Sinucon linked to any psychological or mood side effects?

Yes. Official labeling for Sinucon lists potential side effects that affect the central nervous system, which includes possible changes in mental status or mood. These effects may include confusion, irritability, depression, or hallucinations.


Q: Does official evidence support the use of Sinucon in all types of related conditions?

Official regulatory evidence supports the use of Sinucon for the temporary relief of symptoms related to hay fever, allergies, and the common cold. Its use is limited to these specific, officially approved indications and is not generally supported for other related conditions.


Q: Does Sinucon contain any ingredients that cause allergic reactions?

Yes. Regulatory warnings state that a severe allergic response, such as anaphylaxis, is a possible serious adverse reaction. The potential for a severe allergic response is why regulatory documents specify that patient allergies to the components be noted.


Q: What is the typical time frame for re-evaluation by a healthcare provider while using Sinucon?

Official information advises that treatment with Sinucon should not typically exceed seven days. If symptoms do not show improvement within this time frame, the regulatory guidance is that further consultation with a healthcare provider is generally warranted.


Q: What happens if I forget to take a dose of Sinucon?

Official patient information outlines a regulatory principle for managing missed doses. This guidance typically directs users to prioritize the next scheduled dose, thereby avoiding taking two doses too closely together.


Q: Can Sinucon interact with common pain relievers like acetaminophen or ibuprofen?

Regulatory documents examine the potential for interactions when Sinucon is taken concurrently with other common medications. Official information addresses the co-administration of Sinucon's components with pain relievers such as acetaminophen or ibuprofen.


Q: Does Sinucon affect my appetite?

Yes. Loss of appetite, medically referred to as anorexia, is documented in the official regulatory product labeling as a potential side effect of Sinucon.


Q: Is Sinucon available in generic form?

Regulatory documents and approvals confirm that generic equivalents of fixed-dose combination products containing Sinucon’s active ingredients are available. These generic products are confirmed by regulatory agencies to be bioequivalent to the branded formulation.


Q: Are there any specific vitamins or supplements that are known to interact with Sinucon?

Official drug interaction lists for this medicine's class commonly include warnings against co-administration with certain herbal supplements. These include supplements that may affect the central nervous system or contain sympathomimetic properties, such as Ma Huang (Ephedra) or Kava.


Q: Is Sinucon a controlled substance?

The base active ingredients in Sinucon—the antihistamines and decongestants—are not generally listed under the Controlled Substances Act. The overall regulatory classification for controlled substances depends entirely on the specific formulation of the final product.


Q: Can Sinucon cause changes in vision?

Yes. Official product labeling indicates that visual disturbances are possible side effects. These include symptoms such as blurred vision or double vision. Additionally, serious eye issues like sudden vision loss are listed in regulatory warnings for its components.


Q: Does Sinucon interact with herbal remedies like St. John's Wort?

Official interaction lists for this drug class often contain warnings regarding co-administration with certain herbal remedies. For instance, St. John’s Wort is sometimes noted for its potential to affect drug concentrations in the body or increase the risk of certain side effects.

How should Sinucon be stored and disposed of?

How to Store and Dispose of Sinucon?

Sinucon must be stored according to specific regulatory guidelines to maintain its stability and effectiveness.

Storage Requirement Official Guideline
Temperature Store at room temperature (20-25°C or 68-77°F).
Protection Keep the medication away from light, moisture, and excessive heat. Liquid forms must not be frozen.
Access Keep all medication out of the reach of children and pets.

Disposal of Unused or Expired Medication

When Sinucon is no longer needed or has expired, it must be properly discarded. Do not flush this medication down a toilet or pour it into a drain unless a specific take-back program or local instruction advises this. For safe disposal, consult a pharmacist or local waste disposal company for guidance on appropriate, secure methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sinucon found in:

A-Z Index: